Angiogenesis
Researchers from University of Napoli Federico II detail findings in angiogenesis
Published in Cancer Weekly, August 28th, 2007
A new study, "TLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts," is now available. According to a study from Napoli, Italy, "Synthetic agonists of Toll-like receptor 9 (TLR9), a class of agents that induce specific immune response, exhibit antitumor activity and are currently being investigated in cancer patients. Intriguingly, their mechanisms of action on tumor growth and angiogenesis are still incompletely understood."
"We recently discovered that a synthetic agonist of TLR9, immune modulatory oligonucleotide (IMO), acts by impairing epidermal growth factor receptor (EGFR) signaling...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2007-08-28)
More Articles from Cancer Weekly
- Cancer Vaccines
HPV vaccine does not appear to be effective for treating pre-existing HPV infection - University of Calgary
Invasion of the brain tumors - Bedford Laboratories
Bedford Laboratories Begins Shipping Pentostatin for Injection - Bedford Laboratories
Bedford Laboratories to Begin Shipping Pentostatin for Injection - Bioengineering
ADVENTRX Announces Fast Track Designation Granted By the FDA for CoFactor for the Treatment of Metastatic Colorectal Cancer - Bioengineering
Bradmer announces Dr. Phil Gold to join Board of Directors - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
